Live Chat ×
Skip to main content

IGH deletions in multiple myeloma can enhance risk stratification

From the 2020 Joint Annual Meeting (June 29, 2020)
Presented by Scott Smith, MD
Risk stratification in multiple myeloma is partly based on cytogenetics. IGH deletions were identified in 229 cases referred for clinical testing. Of all deletions identified, 21% resulted in a gene fusion, 7% of which were identified in high-risk fusions. These results and clinical implications of this study will be discussed.

LEARNING OBJECTIVES
At the conclusion of this presentation, participants will be able to:

  1. Identify multiple myeloma cases that warrant follow-up testing.
  2. Summarize the clinical implications associated with IGH deletions as identified using FISH.
  3. Classify the likely gene fusions found from telomeric and centromeric IGH deletions.

CE ACCREDITATION
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Cytogenetics/Molecular Biology will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.